Invesco Ltd. Buys 111,826 Shares of Boston Scientific Corporation $BSX

Invesco Ltd. increased its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 0.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,963,344 shares of the medical equipment provider’s stock after purchasing an additional 111,826 shares during the period. Invesco Ltd.’s holdings in Boston Scientific were worth $1,656,131,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. FWL Investment Management LLC bought a new position in Boston Scientific during the second quarter worth about $26,000. Steph & Co. bought a new stake in shares of Boston Scientific in the 3rd quarter valued at about $25,000. Murphy & Mullick Capital Management Corp increased its stake in shares of Boston Scientific by 200.0% in the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 170 shares during the last quarter. Financial Consulate Inc. acquired a new stake in shares of Boston Scientific in the 3rd quarter valued at approximately $25,000. Finally, United Community Bank boosted its stake in Boston Scientific by 115.7% during the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 147 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Performance

Shares of BSX opened at $68.62 on Friday. The firm has a market cap of $101.82 billion, a P/E ratio of 35.37, a PEG ratio of 0.97 and a beta of 0.69. Boston Scientific Corporation has a twelve month low of $67.56 and a twelve month high of $109.50. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. The firm’s 50 day moving average price is $82.98 and its two-hundred day moving average price is $93.64.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The company had revenue of $5.29 billion during the quarter, compared to the consensus estimate of $5.29 billion. During the same quarter in the prior year, the firm earned $0.70 earnings per share. The firm’s revenue was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently issued reports on BSX shares. Stifel Nicolaus decreased their price objective on shares of Boston Scientific from $125.00 to $110.00 and set a “buy” rating for the company in a report on Wednesday, February 4th. Wells Fargo & Company reduced their price target on shares of Boston Scientific from $125.00 to $94.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Weiss Ratings lowered shares of Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a report on Wednesday, February 4th. Barclays lowered their price objective on shares of Boston Scientific from $136.00 to $124.00 and set an “overweight” rating for the company in a research report on Tuesday, February 3rd. Finally, Evercore dropped their price objective on Boston Scientific from $112.00 to $96.00 and set an “outperform” rating on the stock in a research note on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $108.00.

Insiders Place Their Bets

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.50% of the company’s stock.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Citigroup lowered its price target for BSX from $102 to $94 but kept a Buy rating, which still implies significant upside from current levels and signals some analyst confidence in the company’s fundamentals. Article Title
• Neutral Sentiment: Zacks published a market‑move note explaining the stock’s drop today, providing context on trading and investor reaction rather than new company fundamentals. Why Boston Scientific (BSX) Dipped
• Neutral Sentiment: Multiple law firms are circulating investor notices and deadline reminders (lead‑plaintiff motions due May 4, 2026). These solicitations increase headline volume and may drive short‑term selling even before any case merits are resolved. Example notices: Pomerantz and Robbins Geller. Pomerantz Investor Alert Robbins Geller Notice
• Negative Sentiment: A filed securities class action alleges executives misrepresented U.S. electrophysiology procedure volumes — if these allegations gain traction they could lead to regulatory scrutiny, litigation costs or reputational damage. Lawsuit Allegations
• Negative Sentiment: Unusually heavy put‑option buying has been reported, suggesting some traders are positioning for further near‑term downside or hedging against headline risk. That activity can amplify intraday declines. Put Options Activity

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.